Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 18/20 | 0.43 |
| ▸ | GUCY1A2 | P33402 | 18/20 | 0.43 |
| ▸ | GUCY1A1 | Q02108 | 18/20 | 0.43 |
| ▸ | GUCY1B1 | Q02153 | 18/20 | 0.43 |
| ▸ | BUB1 | O43683 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16806615 | 0.86 | GUCY1B2 (0.47) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1BUB1 | |
| SCHEMBL16806869 | 0.81 | GUCY1B2 (0.53) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1BUB1 | |
| SCHEMBL16906974 | 0.74 | GUCY1B2 (0.47) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL16807001 | 0.74 | GUCY1B2 (0.55) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1BUB1 | |
| SCHEMBL17621741 | 0.74 | GUCY1B2 (0.55) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL16806828 | 0.73 | GUCY1B2 (0.66) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL16082142 | 0.73 | GUCY1B2 (0.46) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL16806827 | 0.73 | GUCY1B2 (0.66) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL20309920 | 0.73 | GUCY1B2 (0.45) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1BUB1 | |
| SCHEMBL17481654 | 0.72 | GUCY1B2 (0.45) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160324856-A1 | USE OF SGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | CYCLERION THERAPEUTICS, INC. | 2016-11-10 | — | — | US | disclosed |
| US-20160311826-A1 | SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324856-A1 | USE OF SGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | SMN1; SMN2, PRKG1, GUCY1A2 | GUCY1B2 8/4885GUCY1A2 3/4885GUCY1A1 6/4885 |
| US-20160311826-A1 | SGC STIMULATORS | GUCY1A1, GUCY1B1, GUCY1A2 | GUCY1B2 4/4885GUCY1A2 3/4885GUCY1A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.